Drug Type Small molecule drug |
Synonyms SYH2039 |
Target |
Mechanism Mat2A inhibitors(S-adenosylmethionine synthase isoform type-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | IND Approval | CN | 18 Mar 2024 | |
Bladder Cancer | Preclinical | CN | - | |
Gastrooesophageal junction cancer | Preclinical | CN | - | |
Glioma | Preclinical | CN | - | |
Non-Small Cell Lung Cancer | Preclinical | CN | - | |
Pancreatic Cancer | Preclinical | CN | - |